LabConnect Appoints Bill Finger as Senior Vice President of Global Strategic Services

LabConnect has announced the appointment of Bill Finger as Senior Vice President of Global Strategic Services, effective September 10, 2025. Finger brings over 25 years of diagnostics and clinical research experience to the role, with extensive expertise in the global laboratory and pharmacy industry. His background positions him as an innovative leader with demonstrated ability to develop strategy, drive execution, and enhance organizational performance while maintaining operational excellence.

Finger's most recent position was Vice President and General Manager of Pharma Services at Quest Diagnostics. His previous experience includes serving as Chief Operating Officer for Interpace Pharma Solutions and Executive Vice President of Precision Medicine and Pharma for Cancer Genetics. He also held leadership roles in scientific affairs and biorepository operations at LabCorp, providing him with comprehensive industry knowledge.

In his new capacity at LabConnect, Finger will oversee the company's Scientific Services, Consulting Services, Data Management, and Functional Service Provider (FSP) teams. This appointment signals LabConnect's commitment to strengthening its leadership in supporting complex clinical studies, particularly in areas such as immuno-oncology, cell and gene therapies, and rare diseases.

Wes Wheeler, LabConnect CEO, emphasized the significance of this appointment, stating that Finger's diagnostic and clinical research leadership represents a valuable asset to the organization. His experience is expected to help the company better anticipate client needs, deliver innovative solutions, and maintain operational excellence for clients worldwide. For additional information about LabConnect's services, visit https://www.labconnect.com.

The appointment of an executive with Finger's credentials reflects the growing importance of specialized laboratory services in the pharmaceutical and biotechnology sectors. As clinical trials become increasingly complex, particularly in advanced therapeutic areas, companies require partners with deep expertise in diagnostic testing, data management, and strategic consulting. This leadership addition may enhance LabConnect's ability to support drug development companies navigating the challenges of modern clinical research.

For the clinical research industry, this move underscores the critical role that experienced leadership plays in ensuring the success of complex studies. Finger's background in both diagnostic services and pharmaceutical partnerships positions him to bridge the gap between laboratory operations and clinical development needs, potentially improving efficiency and outcomes for sponsors conducting cutting-edge research.